| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- manufacturers
- NAT
-
- $89.00
-
2026-04-22
- CAS:831243-31-3
- Purity: 99.65%
- Supply Ability: 10g
|
| | Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- Basic information |
| | Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- Chemical Properties |
| Boiling point | 529.2±45.0 °C(Predicted) | | density | 1.169±0.06 g/cm3(Predicted) | | solubility | DMSO : ≥ 100 mg/mL (334.05 mM) | | form | Solid | | pka | 9.98±0.26(Predicted) | | color | White to off-white |
| | Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- Usage And Synthesis |
| Uses | NAT is an initial hit of NAMPT activator. NAMPT is the rate-limiting enzyme in the NAD salvage pathway, which makes it an attractive target for the research of many diseases associated with NAD exhaustion such as neurodegenerative diseases[1]. | | in vivo | NAT (30 mg/kg, ip, every day for 2 weeks) increases the mechanical hyperalgesia threshold, and exhibits neuroprotective effect in chemotherapy-induced peripheral neuropathy (CIPN) mouse model[1]. | Animal Model: | Chemotherapy-induced peripheral neuropathy (CIPN) mouse model[1] | | Dosage: | 30 mg/kg | | Administration: | ip, every day for 2 weeks | | Result: | Increased the mechanical pain threshold of mice, increased the level of NAD in the sciatic nerves. |
| | References | [1] Wang L, et al. Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy [published online ahead of print, 2022 Mar 16]. Eur J Med Chem. 2022;236:114260. DOI:10.1016/j.ejmech.2022.114260 |
| | Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- Preparation Products And Raw materials |
|